Life Sciences VCLink’s Post

Meet IntraGel Therapeutics, an Asper Prize 2024 Finalist! What is their #StartupStory? Intragel, founded in 2021 by CEO Peter Siman after his mother’s death from untreatable lung cancer, addresses the needs of 8 million inoperable cancer patients. About 40% of these patients, like Peter’s mother, cannot undergo chemotherapy due to toxicity concerns. Intragel’s innovation, SRGel, is a patent-protected gel-like polymer capable of incorporating up to 50% drug payload. Applied directly into tumors, SRGel releases the drug over several weeks, replacing multiple chemotherapy courses, enhancing intratumoral drug concentration and efficacy with minimal systemic toxicity, hitting the jackpot of interventional oncology space. This breakthrough technology showed promise in Phase 1 clinical trials for chemo- and radio-resistant Head and Neck cancer.  Intragel is currently raising $10 million to finalize Phase I trials, build a GMP production facility, execute Phase II trials, and fund marketing efforts. Follow along to see if they will be the rising Startup of the year! The Hebrew University of Jerusalem, Asper Foundation, Yissum, The Hebrew University Tech Transfer Company, Amnon Dekel, PhD, Peter Siman Bridges Israel, Deep Insight, Grove Ventures, JVP, Meron Capital, OurCrowd, PICO Venture Partners , Target Global, 10D #technology #startup #innovation #asperprize 

BioSapien Raises $5.5M to Revolutionize Cancer Drug Delivery! BioSapien, a UAE-based biotech firm, secured $5.5M in Pre-Series A funding led by Global Ventures and Dara Holdings. The funding will drive clinical trials in Abu Dhabi (Q2 2025), product development, and talent acquisition. The company's innovative drug delivery platform targets localized cancer treatment, promising more efficient and safer therapies. BioSapien specializes in local drug delivery for cancer treatment, focusing on colorectal cancer with plans to expand to pancreatic and lung cancers. Their patented technology ensures higher drug concentration near tumors, reducing systemic exposure and side effects. BioSapien founded in 2018 Khatija A., CEO& founder Investors: Backed by Global Ventures and dara holdings. Stay updated with the latest breakthroughs in biotech and startups by following us for more inspiring stories. #BioSapien #CancerTreatment #StartupFunding #BiotechInnovation #HealthTech

VerImmune, a biotechnology company, raised $4.5 million in funding to expand its development efforts. Beiley Biofund led the round. New investors, including Dr. John Ballantyne, PhD, co-founder and former CSO at Aldevron, alongside returning investors Proxima Ventures, Mana Ventures, Gaingels, and others, also participated. The company is developing a virus-inspired particle (ViP) platform technology that can potentially treat multiple diseases, particularly cancer. The ViP technology enables a first-in-class cancer immunotherapy approach known as anti-tumor immune redirection (AIR). This method harnesses the body's immune system to combat cancer by leveraging the immune memory from past infections or childhood vaccination. VerImmune's technology holds immense potential to revolutionize the Immuno-Oncology market, offering new treatment possibilities for patients facing limited options or resistance to current cancer therapies. https://lnkd.in/gKii33aW

🎯 The future of cancer treatment is at our doorstep, thanks to groundbreaking collaborations! Discover how Adcendo and Duality Biologics are reshaping the biotech landscape with their expansion in ADC development. 🔍 Why does this matter? With ADCs offering precise, targeted treatment for cancer, strategic partnerships like this one are paving the way for faster, more effective therapies. 🚀 Entrepreneurs & investors, take note! This trend not only signals innovation in treatment but also highlights a lucrative opportunity for those looking to innovate or invest in the biotech sector. Eager to learn how you can leverage this biotech evolution? Dive into our latest blog exploring actionable insights on capitalizing this trend. Share your thoughts below! 👇 #BiotechTrends #CancerResearch #Innovation #Entrepreneurship

Edgewood Oncology Raises $20M in Series A Funding Edgewood Oncology, a Brookline, MA-based clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors, raised $20M in Series A funding. The round was led by Alta Partners. The company intends to use the funds to advance the clinical development of BTX-A51 in acute myeloid leukemia (AML) and a precision medicine approach to breast cancer. Led by CEO David N. Cook, Edgewood Oncology is a clinical-stage biotechnology company advancing BTX-A51 for patients with hematologic malignancies and genetically-defined solid tumors. "Congratulations to Edgewood Oncology on securing $20M in Series A funding! This significant investment led by Alta Partners underscores the confidence in Edgewood's innovative approach to treating hematologic malignancies and genetically-defined solid tumors. With CEO David Cook & Co- founder Zung Thai at the helm, Edgewood Oncology is poised to advance the clinical development of BTX-A51, offering hope to patients battling acute myeloid leukemia and breast cancer. We eagerly anticipate the positive impact of these advancements in the field of oncology." - says Dr. Shishir Gupta, Founder and CEO of StartupLanes. #startup #funding #fundingnews #investment #startups #startuplanes #startupnews #investmentnews #startupbusiness #FinancingSuccess #InnovationJourney For rectification/nomination reach out to swati@startuplanes.com or +91 7982899391. Kindly only contact us during office hours, i.e., 10 am- 6 pm (Monday to Saturday)

Oncolytic bacteria as developed by synbio specialist Shenzhen Synthetica Pioneering Co. Ltd are a good investment, according to Boehringer Ingelheim's Venture Fund who co-led a Series A financing with Temasek. In mouse models of melanoma, bladder and in situ colorectal cancer, Synthetica's preclinical lead DB1 significantly reduced tumour proliferation and prevented formation of induced metastases. Cancer cell-specific payloads expression is assured by a genetic circuit that that includes a two-fold switch that has a sensor for tumour microenvironment-selective targets. Tremendous approach! https://lnkd.in/eJuM_NV9

Our recent announcement that we raised $132.5 million in an oversubscribed Series C financing is a crucial step in our mission to develop transformational medicines that may restore hope for patients with intractable diseases.   Innovation and the potential to change treatment expectations are made possible by the support of our #investors. Read more about what we mean by Disrupting Disease, Restoring Hope and last month’s #SeriesC financing announcement in this BioPharma Dive article: https://bit.ly/3Ud6YD4   #biotechnews #biotech #fundraising #venturecapital #oncology #lungdiseases 

🚀 BillionToOne Secures $130M to Expand Screening and Oncology Businesses! 🧬 We are thrilled to announce that BillionToOne, a molecular diagnostics pioneer, has raised $130M in an oversubscribed Series D funding round! This funding will drive the expansion of their groundbreaking prenatal screening and oncology diagnostics businesses. 📈 Key Highlights: -Funding Round Led by: Premji Invest, with substantial contributions from Neuberger Berman and existing investors including Baillie Gifford, Adam Street Partners, Hummingbird Ventures, Libertus Capital, Civilization Ventures, and Fifty Years. -Innovative Technology: BillionToOne’s Quantitative Counting Templates (QCTs) technology has been instrumental in developing their diagnostic tests. -Impressive Reach: Over 500,000 patients have benefitted from their diagnostics, generating $125M in annual recurring revenue in just four years. -UNITY Fetal Risk Screen: The first prenatal test capable of assessing fetal risk for genetic conditions without partner samples. -Oncology Liquid Biopsy Products: Northstar Select and Northstar Response offer superior detection and monitoring for late-stage cancer patients. 🔬 Advanced Capabilities: -Northstar Select: Detection limit up to 5x lower than competing assays. -Northstar Response: Offers 10x the precision of single nucleotide variant-based assays. 🎯 Looking Ahead: With this latest funding, BillionToOne’s total capital raised approaches $400M. The company is poised to further revolutionize the diagnostics landscape, enhancing options for clinicians across various specialties. 💬 Quote from Akshay Rai: “BillionToOne has made great progress in transforming the prenatal segment and we are excited by the platform’s potential in expanding diagnostics options available to clinicians in other specialties.” Congratulations to the BillionToOne team for this incredible milestone! #Biotech #Diagnostics #FundingNews #Innovation #PrenatalScreening #Oncology #LiquidBiopsy #Healthcare #MedicalResearch #StartupSuccess #InvestInHealth 💡💉📈

#𝐒𝐮𝐜𝐜𝐞𝐬𝐬𝐒𝐭𝐨𝐫𝐲𝟑 Continuing the series of spotlighting o2h Kickstarter winners and celebrating their success stories, this time we are excited to introduce our latest winner, Palm Therapeutics. Palm Therapeutics, a #USA-based biotech startup in cancer research, is redefining the field with its development of depalmitoylating molecules (DPALMs) that target protein palmitoylation - a novel approach to inhibiting protein function. Their NRas-targeted DPALMs have shown significant in vitro and in vivo efficacy in NRas-driven melanoma models. Palm Tx’s has also been recognised as a 2024 cool company by Connect. Read here - https://lnkd.in/gcYyQ8wu Their innovative work is positively impacting cancer research, and we are proud to support their journey towards finding novel drugs for unmet patient needs and ultimately improving human health! o2h Discovery has supported many early-stage biotech startups through the Kickstarter Award. Our latest edition, 𝐨𝟐𝐡 𝐊𝐢𝐜𝐤𝐬𝐭𝐚𝐫𝐭𝐞𝐫: 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐞 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 is 𝐧𝐨𝐰 𝐥𝐢𝐯𝐞, which is exclusively designed to provide scientific expertise to USA-based biotech startups. If this sounds like a fit for you and you’d like to avail the benefits, below is the link to register your interest and be a part of our success stories. 👉 https://lnkd.in/dAxrjKjn Andrew Rudd Digital Elevator Altitude Marketing Samba Scientific Alchemist Accelerator BioGenerator Ventures BioMotiv #Biotech #Proteomics #DrugDiscovery #Oncology #Innovation #Testimonial #o2hKickstarter #ClientStory #SeedingNewIdeas #CancerResearch

BioSapien, an Abu Dhabi-based #biotech startup focused on drug delivery for localized cancer treatment, recently announced the successful completion of a $5.5 million pre-Series A funding round! Learn more about the transaction and Wilson Sonsini team, led by Mark Solakian, Tamara Labanowski, and Rebecca Lilley (Fliegel), at: https://lnkd.in/ghbzWtWa